
Sintx Technologies, Inc. (NASDAQ:SINT – Free Report) – Research analysts at Ascendiant Capital Markets boosted their Q3 2026 earnings estimates for Sintx Technologies in a note issued to investors on Wednesday, September 30th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will post earnings of ($0.33) per share for the quarter, up from their prior estimate of ($0.54). Ascendiant Capital Markets has a “Buy” rating and a $12.50 price objective on the stock. The consensus estimate for Sintx Technologies’ current full-year earnings is ($1.67) per share. Ascendiant Capital Markets also issued estimates for Sintx Technologies’ Q4 2026 earnings at ($0.32) EPS, Q1 2027 earnings at ($0.30) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.30) EPS, Q4 2027 earnings at ($0.30) EPS and FY2027 earnings at ($1.21) EPS.
Sintx Technologies (NASDAQ:SINT – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Sintx Technologies had a negative net margin of 848.20% and a negative return on equity of 354.44%. The firm had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.46 million.
Get Our Latest Stock Report on SINT
Sintx Technologies Stock Performance
NASDAQ SINT opened at $2.18 on Tuesday. Sintx Technologies has a 52 week low of $1.40 and a 52 week high of $4.64. The company has a 50 day moving average price of $1.73 and a 200 day moving average price of $2.03.
Sintx Technologies Company Profile
SINTX Technologies, Inc is an advanced materials company that develops and manufactures silicon nitride-based ceramics. Its technology is designed to provide properties such as high strength, wear resistance, biocompatibility and antimicrobial performance, supporting applications in healthcare and other demanding industries.
The company’s medical activities have focused on ceramic components and implantable products for orthopedic and spinal procedures, including technologies used in spinal fusion and other reconstructive applications.
Recommended Stories
- Five stocks we like better than Sintx Technologies
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Sintx Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sintx Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
